gefitinib has been researched along with moricizine in 2 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (moricizine) | Trials (moricizine) | Recent Studies (post-2010) (moricizine) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 365 | 85 | 18 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Astolfi, A; Barreca, ML; Cecchetti, V; Felicetti, T; Iraci, N; Kaatz, GW; Manfroni, G; Massari, S; Pietrella, D; Sabatini, S; Tabarrini, O | 1 |
1 review(s) available for gefitinib and moricizine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for gefitinib and moricizine
| Article | Year |
|---|---|
Pharmacophore-Based Repositioning of Approved Drugs as Novel Staphylococcus aureus NorA Efflux Pump Inhibitors.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Drug Repositioning; Humans; Ligands; Models, Molecular; Multidrug Resistance-Associated Proteins; Staphylococcal Infections; Staphylococcus aureus | 2017 |